European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Meta Expands AI Training With Employee Activity Tracking Tools 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
TUSTIN, Calif., March 09, 2017 -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is payable on April 3, 2017 to holders of record at the close of business on March 20, 2017.
The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2017 through March 31, 2017. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
